Award recordCONTRACT

THE HARVARD DRUG GROUP, L.L.C.

PIID 36E79725D0001· VA Staff Offices· NAC PHARMACEUTICALS (36E797)· 6505 · DRUGS AND BIOLOGICALS· FY2025· $0 net obligations· UEI CBGGKKVNJBK9· TN

Description

MODIFICATION TO IMPLEMENT EO 14398 DEI DISCRIMINATION IN TO NATIONAL CONTRACT 36E79725D0001.

Base award description: NEW AWARD FOR LURASIDONE HCL TABLETS WITH THE HARVARD DRUG GROUP, L.L.C. DBA MAJOR PHARMACEUTICALS. BASE YEAR ORDERING PERIOD IS 12/10/2024 TO 12/09/2025 WITH FOUR ONE-YEAR OPTIONS.

First action · last action
2024-10-10 · 2026-08-31
Transactions
5
First transaction's obligation
$0
Base + all options value (sum of deltas)
$10,056,938
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
5
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 5 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$1$0Base award · 2024-10-10 · this action $0 · running total $0Modification P00001 · 2025-07-16 · this action $0 · running total $0Modification P00002 · 2025-11-07 · this action $0 · running total $0Modification P00003 · 2026-08-10 · this action $0 · running total $0Modification P00004 · 2026-08-31 · this action $0 · running total $0
  • Base2024-10-10+$0= $0
  • Mod P000012025-07-16+$0= $0
  • Mod P000022025-11-07+$0= $0
  • Mod P000032026-08-10+$0= $0
  • Mod P000042026-08-31+$0= $0
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2024-10-10+$0$0NEW AWARD FOR LURASIDONE HCL TABLETS WITH THE HARVARD DRUG GROUP, L.L.C. DBA MAJOR PHARMACEUTICALS. BASE YEAR…
Mod P00001· ADD SUBCONTRACTING PLAN2025-07-16+$0$0INCORPORATE THE HARVARD DRUG GROUP, L.L.C. DBA MAJOR PHARMACEUTICALS FY26 SUBK PLAN INTO CONTRACT. PLAN EFFECT…
Mod P00002· EXERCISE AN OPTION2025-11-07+$0$0EXERCISE THE FIRST OPTION YEAR FOR LURASIDONE HCL TABLETS CONTRACT 36E79725D0001 WITH THE HARVARD DRUG GROUP,…
Mod P00003· ADD SUBCONTRACTING PLAN2026-08-10+$0$02027 SUBCONTRACTING PLAN EFFECTIVE 7/1/2026 THOUGH 6/30/2027 FOR LURASIDONE HCL TABLETS WITH THE HARVARD DRUG…
Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE2026-08-31+$0$0MODIFICATION TO IMPLEMENT EO 14398 DEI DISCRIMINATION IN TO NATIONAL CONTRACT 36E79725D0001.

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI CBGGKKVNJBK9)

AwardOffice · PSC / listingNet obligationsFY
36F79725D0121NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS$0FY2025
36E79725D0010NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2025
36E79722D0017NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2022
36E79721D0048NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2021
36E79721D0038NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2021
36F79719D0033NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS$0FY2019

Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)

AwardRecipientOfficeNet obligationsFY
36E79726A0025CHIESI USA INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0024NEUROTECH PHARMACEUTICALS, INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0023TAKEDA PHARMACEUTICALS AMERICA, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726D0041GOLDEN STATE MEDICAL SUPPLY, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0022AURINIA PHARMA US INCNAC PHARMACEUTICALS (36E797)$0FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79725D0001_3600 · retrieved 2026-09-26.